Register a trial

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05844449




Registration number
NCT05844449
Ethics application status
Date submitted
24/04/2023
Date registered
6/05/2023

Titles & IDs
Public title
Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older
Scientific title
A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 1 Year of Age and Older
Secondary ID [1] 0 0
2022-503081-74-00
Secondary ID [2] 0 0
VX22-121-106
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Cystic Fibrosis 0 0
Condition category
Condition code
Human Genetics and Inherited Disorders 0 0 0 0
Cystic fibrosis
Respiratory 0 0 0 0
Other respiratory disorders / diseases
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Inflammatory and Immune System 0 0 0 0
Connective tissue diseases
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - VNZ/TEZ/D-IVA

Experimental: VNZ/TEZ/D-IVA - Participants (Cohort 1: 6 through 11 years of age (inclusive); Cohort 2: 2 through 5 years of age (inclusive) and Cohort 3: 1 to less than (\<) 2 years of age) will receive VNZ/TEZ/D-IVA once daily at doses determined based on their age and weight. The age range is based on date of informed consent in parent study.


Treatment: Drugs: VNZ/TEZ/D-IVA
Fixed-dose combination tablets for oral administration.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs)
Timepoint [1] 0 0
From Day 1 up to Week 100
Secondary outcome [1] 0 0
All Cohorts: Absolute Change in Sweat Chloride (SwCl)
Timepoint [1] 0 0
From Baseline Through Week 96
Secondary outcome [2] 0 0
Cohort 1: Absolute Change in Percent Predicted Forced Expiratory Volume (ppFEV1)
Timepoint [2] 0 0
From Baseline Through Week 100
Secondary outcome [3] 0 0
All Cohorts: Number of Pulmonary Exacerbation (PEx) Related Hospitalizations
Timepoint [3] 0 0
From Baseline Through Week 100
Secondary outcome [4] 0 0
All Cohorts: Number of CF- Related Hospitalizations
Timepoint [4] 0 0
From Baseline Through Week 100
Secondary outcome [5] 0 0
Cohort 1: Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain (RD) Score
Timepoint [5] 0 0
From Baseline Through Week 100
Secondary outcome [6] 0 0
Cohorts 1 and 2: Absolute Change in Body Mass Index (BMI)
Timepoint [6] 0 0
From Baseline Through Week 100
Secondary outcome [7] 0 0
Cohorts 1 and 2: Absolute Change in BMI-for-age Z-score
Timepoint [7] 0 0
From Baseline Through Week 100
Secondary outcome [8] 0 0
Cohort 3: Absolute Change in Weight-for-length
Timepoint [8] 0 0
From Baseline Through Week 100
Secondary outcome [9] 0 0
Cohort 3: Absolute Change in Weight-for-length Z-score
Timepoint [9] 0 0
From Baseline Through Week 100
Secondary outcome [10] 0 0
All Cohorts: Absolute Change in Weight
Timepoint [10] 0 0
From Baseline Through Week 100
Secondary outcome [11] 0 0
All Cohorts: Change in Weight-for-age Z-score
Timepoint [11] 0 0
From Baseline Through Week 100
Secondary outcome [12] 0 0
Cohorts 1 and 2: Absolute Change in Height
Timepoint [12] 0 0
From Baseline Through Week 100
Secondary outcome [13] 0 0
Cohorts 1 and 2: Absolute Change in Height-for-age Z-score
Timepoint [13] 0 0
From Baseline Through Week 100
Secondary outcome [14] 0 0
Cohort 3: Absolute Change in Length
Timepoint [14] 0 0
From Baseline Through Week 100
Secondary outcome [15] 0 0
Cohort 3: Absolute Change in Length-for-age Z-score
Timepoint [15] 0 0
From Baseline Through Week 100

Eligibility
Key inclusion criteria
Key

* Participants who have completed study drug treatment in the parent study (VX21-121-105; NCT Number: NCT05422222)

Key
Minimum age
1 Year
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Hepatic cirrhosis with portal hypertension, moderate hepatic impairment, or severe hepatic impairment that might pose an additional risk in administering study drug
* History of solid organ, hematological transplantation, or cancer
* History of drug intolerance in the parent study

Other protocol defined Inclusion/Exclusion criteria may apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Not applicable
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
11/08/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/10/2030
Actual
Sample size
Target
180
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Women & Children's Hospital - North Adelaide
Recruitment hospital [2] 0 0
The Royal Childrens Hospital - Parkville
Recruitment hospital [3] 0 0
Queensland Children's Hospital - South Brisbane
Recruitment postcode(s) [1] 0 0
- North Adelaide
Recruitment postcode(s) [2] 0 0
- Parkville
Recruitment postcode(s) [3] 0 0
- South Brisbane
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Colorado
Country [3] 0 0
United States of America
State/province [3] 0 0
Georgia
Country [4] 0 0
United States of America
State/province [4] 0 0
Illinois
Country [5] 0 0
United States of America
State/province [5] 0 0
Indiana
Country [6] 0 0
United States of America
State/province [6] 0 0
Massachusetts
Country [7] 0 0
United States of America
State/province [7] 0 0
Minnesota
Country [8] 0 0
United States of America
State/province [8] 0 0
Missouri
Country [9] 0 0
United States of America
State/province [9] 0 0
New York
Country [10] 0 0
United States of America
State/province [10] 0 0
Ohio
Country [11] 0 0
United States of America
State/province [11] 0 0
Pennsylvania
Country [12] 0 0
United States of America
State/province [12] 0 0
Texas
Country [13] 0 0
United States of America
State/province [13] 0 0
Vermont
Country [14] 0 0
United States of America
State/province [14] 0 0
Wisconsin
Country [15] 0 0
France
State/province [15] 0 0
Bron Cedex
Country [16] 0 0
France
State/province [16] 0 0
Paris Cedex 15
Country [17] 0 0
Germany
State/province [17] 0 0
Berlin
Country [18] 0 0
Germany
State/province [18] 0 0
Essen
Country [19] 0 0
Germany
State/province [19] 0 0
Hannover
Country [20] 0 0
Netherlands
State/province [20] 0 0
Rotterdam
Country [21] 0 0
Sweden
State/province [21] 0 0
Göteborg
Country [22] 0 0
Switzerland
State/province [22] 0 0
Bern
Country [23] 0 0
Switzerland
State/province [23] 0 0
Zürich
Country [24] 0 0
United Kingdom
State/province [24] 0 0
Cardiff
Country [25] 0 0
United Kingdom
State/province [25] 0 0
London

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Vertex Pharmaceuticals Incorporated
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment
Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT05844449